Inflammatory Macrophages in the Sciatic Nerves Facilitate Neuropathic Pain Associated with Type 2 Diabetes Mellitus

Fumihiro Saika,1 Norikazu Kiguchi,1 Shinsuke Matsuzaki,1 Daichi Kobayashi, and Shiroh Kishioka

Department of Pharmacology, Wakayama Medical University, Wakayama, Japan

Received August 5, 2018; accepted December 31, 2018

ABSTRACT

Despite the requirement for effective medication against neuropathic pain associated with type 2 diabetes mellitus (T2DM), mechanism-based pharmacotherapy has yet to be established. Given that long-lasting neuroinflammation, driven by inflammatory macrophages in the peripheral nerves, plays a pivotal role in intractable pain, it is important to determine whether inflammatory macropahges contribute to neuropathic pain associated with T2DM. To generate an experimental model of T2DM, C57BL/6J mice were fed a high-fat diet (HFD) ad libitum. Compared with control diet feeding, obesity and hyperglycemia were observed after HFD feeding, and the mechanical pain threshold evaluated using the von Frey test was found to be decreased, indicating the development of mechanical allodynia. The expression of mRNA markers for macrophages, inflammatory cytokines, and chemokines were significantly upregulated in the sciatic nerve (SCN) after HFD feeding. Perineural administration of saporin-conjugated anti-Mac1 antibody (Mac1-Sap) improved HFD-induced mechanical allodynia. Moreover, treatment of Mac1-Sap decreased the accumulation of F4/80+ macrophages and the upregulation of inflammatory mediators in the SCN after HFD feeding. Inoculation of lipopolysaccharide-activated peritoneal macrophages in tissue surrounding the SCN elicited mechanical allodynia. Furthermore, pharmacological inhibition of inflammatory macrophages by either perineural or systemic administration of TC-2559 [4-(5-ethoxy-3-pyridinyl)-N-methyl-(3E)-3-buten-1-amine difumarate], a 4(92) nicotinic acetylcholine receptor–selective agonist, relieved HFD-induced mechanical allodynia. Taken together, inflammatory macrophages that accumulate in the SCN mediate the pathophysiology of neuropathic pain associated with T2DM. Inhibitory agents for macrophage-driven neuroinflammation could be potential candidates for novel pharmacotherapy against intractable neuropathic pain.

Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease and results in various long-term complications affecting the eyes, kidneys, and peripheral nervous system. Approximately 50% of patients with T2DM experience painful neuropathy (neuropathic pain) (Boulton et al., 2005; Sudore et al., 2012) that is resistant to currently available medications such as opioid analgesics (Barrett et al., 2007). Despite the high prevalence and negative impact on quality of life, the molecular basis of the pathogenesis of neuropathic pain associated with T2DM is yet to be elucidated. Therefore, there is a need to clarify the key components underlying T2DM-related neuropathic pain to establish novel effective pharmacotherapies. Among the variety of basic approaches used to uncover the pathogenesis of complications in T2DM, high-fat diet (HFD)—induced diabetes with obesity has proved to be the most popular experimental model in rodents, being closely correlated with the known pathology of T2DM (Heydemann, 2016). For example, T2DM experimental rodent models induced by HFD feeding and patients with T2DM present hyperexcitability and spontaneous activity of primary sensory neurons reflecting the typical symptoms of neuropathic pain, such as hyperalgesia and allodynia (Baron et al., 2009; Menichella et al., 2014; Jayaraj et al., 2018). Therefore, HFD feeding is also a useful approach to investigate the molecular background of T2DM-related neuropathic pain in rodents.

Emerging evidence suggests that chronic neuroinflammation due to neuroimmune interactions plays a pivotal role in the pathogenesis of intractable neurogenic disorders, such as autoimmune diseases, neurodegenerative diseases, and neuropathic pain (Ubogu et al., 2006; Scholz and Woolf, 2007; Drouin-Ouellet and Cicchetti, 2012). In addition, numerous reports have demonstrated that the infiltration of circulating leukocytes (i.e., monocytes/macrophages and neutrophils) to
the damaged nervous system contributes significantly to chronic neuroinflammation (Liu et al., 2000; Hu and McLachlan, 2002; Thacker et al., 2007; Austin and Moalem-Taylor, 2010; Calvo et al., 2012). Particularly, macrophages account for the largest population among infiltrating leukocytes in injured peripheral nerves, and the depletion of macrophages clearly prevents experimental neuropathic pain in rodents (Liu et al., 2000; Mert et al., 2009; Kobayashi et al., 2015). Moreover, it has been reported that several inflammatory cytokines [e.g., interleukin (IL)-1β and tumor necrosis factor α (TNFα)] and chemokines [e.g., CC-chemokine ligand (CCL) 3 and CCL4], derived from inflammatory macrophages, exert functions as key neuroinflammatory regulators that directly enhance the excitability of primary sensory neurons and prolong neuro-inflammation, facilitating neuropathic pain (Sommer and Kress, 2004; Scholz and Woolf, 2007; Lee and Zhang, 2012; Saika et al., 2012). Given the functional significance of peripheral inflammatory macrophages in the pathogenesis of neuropathic pain, it is worth investigating the pathophysiological roles of such macrophages in T2DM model mice.

The primary aim of this study was to determine whether inflammatory macrophage numbers increased in the peripheral nervous system of the T2DM model mice after HFD feeding and whether inflammatory macrophages contribute to the pathogenesis of T2DM-related neuropathic pain by applying inhibitors of inflammatory macrophages. According to our previous reports, the α4β2 nicotinic acetylcholine receptor (nAChR) ligand TC-2559 difumarate [4-(5-ethoxy-3-pyridinyl)-N-methyl-(3E)-3-buten-1-amine difumarate] is a potent inhibitor of inflammatory macrophages and improved neuropathic pain after peripheral nerve injury in mice (Kiguchi et al., 2015b; Saika et al., 2015). We also evaluated the therapeutic potential of TC-2559 administration targeting peripheral macrophages for T2DM-related neuropathic pain. Such investigations not only provide scientific understanding regarding the pathophysiology of T2DM, but also suggest novel evidence-based pharmacotherapy focusing on peripheral macrophages for intractable neuropathic pain associated with T2DM.

Materials and Methods

Generation of T2DM Mice. All animal experiments were approved by the Animal Research Committees of Wakayama Medical University and were carried out in accordance with the in-house guidelines for the care and use of laboratory animals of Wakayama Medical University. Male C57BL/6J mice, 8 weeks of age (SLC, Hamamatsu, Japan), were used in all experiments, and experiments complied with the Ethical Guidelines of the International Association for the Study of Pain. Mice were housed in plastic cages in a temperature-controlled room (23–24°C, 60%–70% humidity) with a 12-hour dark/light cycle and provided with water and food ad libitum. To induce T2DM and control, mice were fed an HFD (60 kcal% fat; 20% carbohydrate; 20% protein) in a volume of 1 ml. HFD feeding.

Behavioral Testing. For evaluating mechanical allodynia, the 50% withdrawal threshold was determined by the von Frey test in accordance with a previously established method (Chaplan et al., 1994). Briefly, mice were individually placed on a 5 × 5 mm wire mesh grid floor and covered with an opaque acrylic box. After adaptation for 2–3 hours, calibrated von Frey filaments (Neuroscience, Tokyo, Japan) were applied to the middle of the plantar surface of the hind paw through the bottom of the mesh floor. In the paradigm of the up-down method, testing was initiated with a 0.4 g force in the middle of the series (0.02, 0.04, 0.07, 0.16, 0.4, 0.6, 1.0, 1.4, and 2.0g). Stimuli were always presented in a consecutive fashion, either ascending or descending. In the absence of a paw withdrawal response to the selected force, a stronger stimulus was applied. In the presence of paw withdrawal, the next weaker stimulus was chosen. In accordance with the findings by Chaplan et al. (1994), after the response threshold was first crossed (the two responses straddling the threshold), four additional stimuli were applied. Based on the responses to the series of the von Frey filament, the 50% paw withdrawal threshold was calculated.

Whole-Mount Immunohistochemistry. The SCN was collected from mice after transcardiac perfusion with PBS followed by 4% paraformaldehyde and was postfixed in 4% paraformaldehyde at 4°C overnight. The SCN was treated with PBS containing 0.3% Triton X-100 (PBST) for 1 hour and then blocked with 5% normal donkey serum in 0.3% PBST at room temperature for 2 hours. The SCN was then incubated with primary antibodies against F4/80 (rabbit polyclonal, 1:300; Alomone Labs, Jerusalem, Israel) at 4°C overnight. Antibodies were diluted in 1% normal donkey serum in 0.3% PBST at 1:300. The SCN was washed three times with 0.3% PBST and then incubated with fluorescence-conjugated secondary antibodies (1:500; Abcam, Cambridge, MA) at room temperature for 2 hours. The SCN was washed in PBST, and then incubated with Hoechst 33342 stain (Thermo Fisher Scientific, Waltham, MA) at room temperature for 10 minutes. Finally, the SCN was mounted on cover glass, and fluorescence images were immediately acquired using a confocal laser scanning microscope (Carl Zeiss, Oberkochen, Germany). For the quantification of macrophages, the number of F4/80+ cells was measured in a square with an area of 100 × 100 μm².
and was shown as the average of three randomly selected sections from one SCN of each mouse.

**Reverse Transcription-Quantitative Polymerase Chain Reaction.** Mice were euthanized by decapitation, and the fresh SCNs and trigeminal nerves were collected in RNAlater solution (Thermo Fisher Scientific). The TRIzol Plus RNA Purification Kit (Thermo Fisher Scientific) was used for the isolation of total RNA from the tissues following the manufacturer instructions. The SCN was placed in a 1.5-ml RNAase-free tube and homogenized with TRIzol reagent. Chloroform was added to each sample, which was then centrifuged at 4°C for 15 minutes. The aqueous phase containing RNA was transferred to a fresh tube, and RNA was isolated by purification column. Total RNA extract was used for the synthesis of cDNA by reverse transcription (RT) as follows. Total RNA was incubated with Random Primers (Promega, Madison, WI) at 70°C for 5 minutes and then cooled on ice. We then transcribed cDNA by incubation with M-MLV Reverse Transcriptase (Promega) and dNTP mix (Promega) at 37°C for 50 minutes. Quantitative polymerase chain reaction (qPCR) was performed using the AriaMx Real-Time PC System (Agilent Technologies, Santa Clara, CA) with template cDNA, primers for each gene (Thermo Fisher Scientific) and SYBR Premix Ex Taq II (Takara Bio Inc., Kusatsu, Japan). The primer sequences are listed in Table 1. Reactions were performed under the following conditions: 3 minutes at 95°C, followed by 45 cycles of two steps, 10 seconds at 95°C and 30 seconds at 60°C. The fluorescence intensities were recorded, and data were normalized by β-actin (ACTB).

**Statistical Analysis.** Data are presented as the mean ± S.E.M. Statistical analyses were performed using Student’s t test, one-way analysis of variance followed by Tukey’s multiple-comparison test, or two-way analysis of variance followed by Bonferroni’s multiple-comparison test as appropriate. Statistical significance was established at P < 0.05.

**Results**

We first generated the T2DM model mice by HFD feeding ad libitum. The body weight of the HFD group was significantly greater than that of the CD group during the whole experimental period [F(1,126) = 1246.27, P < 0.0001; Bonferroni’s test, P < 0.001; 4–24 weeks; n = 10] (Fig. 1A). The mice exhibited obesity at 16 weeks of HFD feeding compared with CD feeding (Fig. 1B). Blood glucose levels after 4 weeks of HFD feeding were higher than those for CD feeding, and hyperglycemia persisted for at least 24 weeks of feeding [F(1,91) = 123.17, P < 0.0001; Bonferroni’s test, P < 0.05; 4–24 weeks; n = 5–10] (Fig. 1C). The mechanical pain threshold evaluated by the von Frey test was significantly decreased at 8 weeks in contrast to the decrease at least 24 weeks of HFD feeding, indicating long-lasting mechanical allodynia [F(1,100) = 75.23, P < 0.0001; Bonferroni’s test, P < 0.01; 8–24 weeks; n = 8–10] (Fig. 1D).

Next, we investigated macrophage accumulation and the expression of inflammatory mediators in the SCN by RT-qPCR. The mRNA expression levels of inflammatory macrophage markers (F4/80 [F(1,30) = 44.94, P < 0.0001; Bonferroni’s test, P < 0.001; n = 6], CD11b [F(1,30) = 51.70, P < 0.0001; Bonferroni’s test, P < 0.001; n = 6], and cluster of differentiation 68 (CD68) [F(1,30) = 45.08, P < 0.0001; Bonferroni’s test, P < 0.001; n = 6]) and chemokines (CCL3 [F(1,30) = 43.95, P < 0.0001; Bonferroni’s test, P < 0.001; n = 6]) were also upregulated at 16 weeks of HFD feeding in contrast to that after CD feeding (Fig. 2A). Consistently, pain-related inflammatory cytokines (IL-1β [F(1,30) = 19.93, P = 0.0001; Bonferroni’s test, P < 0.01; n = 6] and TNFα [F(1,30) = 9.17, P = 0.0050; Bonferroni’s test, P < 0.05; n = 6]) and chemokines (CCL3 [F(1,30) = 43.95, P < 0.0001; Bonferroni’s test, P < 0.001; n = 6]) were also upregulated at 16 weeks of HFD feeding (Fig. 2B). These expression patterns persisted for 32 weeks of HFD feeding, suggesting the accumulation of inflammatory macrophages and long-lasting neuroinflammation in the SCN. On the other hand, upregulation of neither macrophage markers nor inflammatory cytokines and chemokines was observed in the trigeminal nerves at 16 weeks of HFD feeding (Supplemental Fig. 1).

To determine the contribution of peripheral macrophages to HFD-induced mechanical allodynia, Mac1-Sap (macrophage-targeting toxin, 250 ng) or control saporin (250 ng) was perineurally administered three times, every 2 days after 16 weeks of HFD feeding. HFD-induced allodynia was significantly improved on day 7 after the first Mac1-Sap treatment [F(3,72) = 33.02, P < 0.0001; Bonferroni’s test, P < 0.05; n = 9–11] and had no effect in the CD group. Control saporin did not affect the mechanical pain threshold in either the CD or HFD group (Fig. 3A). We confirmed that F4/80+ macrophages were accumulated in the SCN after 17 weeks of HFD feeding (Fig. 2A). Consistently, pain-related inflammatory mediators in the SCN by immunohistochemistry [F(3,12) = 19.93, P = 0.0001; Bonferroni’s test, P < 0.01; 8–24 weeks; n = 10] (Fig. 1D). The mice showed mechanical allodynia [F(1,100) = 75.23, P < 0.0001; Bonferroni’s test, P < 0.01; 8–24 weeks; n = 8–10] (Fig. 1D).

**Table 1**

<table>
<thead>
<tr>
<th>Primer sequences for RT-qPCR</th>
<th>Forward (5’ to 3’)</th>
<th>Reverse (5’ to 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH</td>
<td>GGTTGTGAAACCGAGAAT</td>
<td>ACTGTGGTCATGGAGCCCTTC</td>
</tr>
<tr>
<td>ACTB</td>
<td>CAGCTGAGGGAAAGCGTG</td>
<td>TCTCCAGGGAGAAAGGAT</td>
</tr>
<tr>
<td>F4/80</td>
<td>AAATCTTACGGCCAGGATG</td>
<td>CCAGGACCGCCAGAACAAAGC</td>
</tr>
<tr>
<td>CD11b</td>
<td>GTTTCATCTGTCCCGAACGA</td>
<td>CGAGGCCCATCATAGAAGAAG</td>
</tr>
<tr>
<td>CD68</td>
<td>ACTCATACCGCCGACCAC</td>
<td>CCAAGCGTGGAGATTCTTG</td>
</tr>
<tr>
<td>IRF5</td>
<td>ACACTGAAAGGGTGAGTGA</td>
<td>GCTTCCATGGAGATTCTTG</td>
</tr>
<tr>
<td>IL-1β</td>
<td>AAAGCTCTTACACCTCTAAG</td>
<td>TGGGAATCTCGGGCTCTAG</td>
</tr>
<tr>
<td>TNFα</td>
<td>CCCGGAGGATGGATGAGT</td>
<td>TGCGGCTACAGGGCTCTAG</td>
</tr>
<tr>
<td>CCL3</td>
<td>CTGCGCTTGGTCTGCTCCTC</td>
<td>GTGTATCTCCGGCGTGAT</td>
</tr>
<tr>
<td>CCL4</td>
<td>ATGGAGCTGCTTGCTGCTGC</td>
<td>GCCGGAGGCTGAAGGAAAG</td>
</tr>
<tr>
<td>TLR4</td>
<td>TGTTGTCTCCTCCGCTGACA</td>
<td>TGTCATACGGAGGCTTG</td>
</tr>
</tbody>
</table>

GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
17 weeks of HFD feeding were decreased by perineural treatment with Mac1-Sap (250 ng), as confirmed by RT-qPCR, supporting the ablation of macrophages (Fig. 4A). In addition, the mRNA expression levels of IL-1β \((t\text{ test}, P < 0.0434; n = 6)\), CCL3 \((t\text{ test}, P < 0.0356; n = 6)\), and CCL4 \((t\text{ test}, P < 0.0318; n = 6)\) after HFD feeding were also decreased after Mac1-Sap treatment, suggesting that inflammatory macrophages play a key role in neuroinflammation in the SCN after HFD feeding (Fig. 4B). The expression levels of these molecules in the SCN after CD feeding were slightly decreased by Mac1-Sap treatment, but those were not significant (Supplemental Fig. 2).

To determine a direct relationship between macrophage accumulation in the SCN and mechanical allodynia, macrophages were inoculated in the tissue surrounding the SCN. Based on the upregulation of toll-like receptor 4 (TLR4) mRNA in the SCN at 16 weeks of HFD feeding \((t\text{ test}, P < 0.0018; n = 6)\) (Supplemental Fig. 3), peritoneal macrophages collected from naive mice were activated by LPS, an exogenous ligand for TLR4, treatment in vitro. The mRNA expression levels of IL-1β \((t\text{ test}, P = 0.0004; n = 3)\), TNFα \((t\text{ test}, P = 0.0055; n = 3)\), CCL3 \((t\text{ test}, P = 0.0026; n = 3)\), and CCL4 \((t\text{ test}, P = 0.0009; n = 3)\) were upregulated at 3 hours after LPS (500 ng/ml) treatment compared with vehicle treatment (Fig. 5A). Subsequently, activated macrophages were perineurally administered to naive mice. The mechanical pain threshold 3 days after the inoculation of LPS-treated macrophages was significantly lower than after vehicle-treated macrophage injection \((t\text{ test}, P < 0.001; n = 8–9)\) (Fig. 5B).

Finally, we investigated whether pharmacological inhibition of macrophages can relieve HFD-induced mechanical allodynia. Consistent with our previous reports showing that the α4β2 subtype of nAChR is a negative regulator of inflammatory macrophages underlying neuropathic pain, the α4 subunit of nAChR was located on accumulated F4/80 macrophages in the SCN after HFD feeding (Fig. 6A). TC-2559, a potent α4β2 nAChR agonist, was perineurally or systemically (subcutaneously) administered once a day for 4 days at 16 weeks of HFD feeding. The perineural administration of TC-2559 (20 nmol) significantly improved HFD-induced mechanical allodynia \([F(4,75) = 25.86, P < 0.0001; \text{Bonferroni’s test}, P < 0.01]\), and it was antagonized by the coadministration of DHβE (40 nmol), an α4β2 nAChR antagonist (Fig. 6B). The relieving effects of perineural administration of TC-2559 were observed in a dose-dependent manner (20 nmol; \(t\text{ test}, P = 0.0008; n = 5)\) (Fig. 6C). Moreover, subcutaneous administration of TC-2559 (10 mg/kg) also relieved HFD-induced mechanical allodynia \((F(3,75) = 38.20, P < 0.0001; \text{Bonferroni’s test}, P < 0.01)\) (Fig. 6D). These relieving effects of TC-2559 (by perineural and subcutaneous administration) persisted for more than 1 week even after drug...
cessation. TC-2559 did not affect the mechanical pain threshold in the CD group.

**Discussion**

The present study provides three novel findings suggesting that inflammatory macrophages in the SCN facilitate neuropathic pain associated with T2DM. First, the accumulation of inflammatory macrophages contributes to long-lasting neuroinflammation in the SCN after HFD feeding. Second, either the ablation of macrophages by cell-specific toxins or the pharmacological inhibition of inflammatory macrophages via a 4b2 nAChR ligand improved HFD-induced mechanical allodynia. Third, inoculation of inflammatory macrophages in the tissue surrounding the SCN elicited mechanical allodynia.

Macrophages, a key component of innate immunity, play critical roles in the regulation of inflammatory responses and in host defense against pathogens (Gordon and Taylor, 2005; Murray and Wynn, 2011; Wynn et al., 2013; Okabe and Medzhitov, 2016). Upon tissue damage or infection, circulating monocytes are generally recruited to the site of damage by chemokine signaling (Murray and Wynn, 2011; Shi and Pamer, 2011; Wynn et al., 2013). Thereafter, monocytes differentiate into macrophages that orchestrate inflammatory responses to repair damaged tissue and resolve the excessive inflammation (Prame Kumar et al., 2018). On the other hand, when nervous systems are damaged, cytokines, chemokines, and damage-associated molecular patterns recruit macrophages into the injured nerves, which elicit nonresolving neuroinflammation (Kiguchi et al., 2017a). Macrophages are not the only cells to accumulate in damaged nerves, as neutrophils and lymphocytes also accumulate there (Perkins and Tracey, 2000; Moalem et al., 2004; Morin et al., 2007); however, macrophages account for the largest population at the middle/late phase after nerve injury (Kiguchi et al., 2017a). This suggests that macrophages may play a pivotal role in the regulation of neuroinflammation and pathologic pain. Notably, the ablation or inhibition of macrophages results in the prevention of experimental neuropathic pain in rodents (Liu et al., 2010; Echeverry et al., 2013; Kiguchi et al., 2014; Kobayashi et al., 2015). Macrophages are often polarized toward functionally distinct phenotypes to regulate complicated inflammatory processes (Ricardo et al., 2008; Murray and Wynn, 2011; Wynn et al., 2013). Inflammatory (M1) macrophages are characterized by higher expression of inflammatory cytokines and chemokines (i.e., IL-1β, TNFα, CCL3, and CCL4) that exacerbate inflammation (Sica and Mantovani, 2012; Wynn and Vannella, 2016; Murray, 2017). In contrast, suppressive (M2) macrophages produce anti-inflammatory cytokines such as IL-10, which suppress and resolve inflammation (Mosser, 2003; Sica and Mantovani, 2012; Wynn and Vannella, 2016; Murray, 2017). Since the balance of macrophage polarization leans to the M1 state in injured nerves, neuroinflammation persists long term and is directly related to chronic pain.

![Figure 2](https://jpet.aspetjournals.org/content/39/3/539/F2.large.jpg)
We have demonstrated that the phenotypic shift of M1 macrophages toward M2 macrophages in injured nerves can relieve neuropathic pain (Kiguchi et al., 2015a, 2017b), supporting the notion that inflammatory macrophages are a fundamental component of neuropathic pain.

Inflammatory macrophages predominantly produce typical inflammatory cytokines (IL-1β and TNFα) and chemokines (CCL3 and CCL4), and those molecules are well known as crucial mediators in various inflammatory diseases (Sica and Mantovani, 2012). Moreover, the inhibition of such molecules effectively improved neuropathic pain after nerve injury in rodents, indicating that cytokines and chemokines may also contribute to the pathogenesis of neuropathic pain (Scholz and Woolf, 2007; Kiguchi et al., 2010; Saika et al., 2012). Under a neuroinflammatory state, inflammatory macrophages interact with the surrounding cells through a cytokine-chemokine network (Gouwy et al., 2005; Becher et al., 2017). Given that these cytokines and chemokines directly sensitize primary sensory neurons through the sensitization of nociceptors, these mediators may contribute significantly to the peripheral regulation of neuropathic pain. Here we show that not only common macrophage markers (e.g., F4/80 and CD11b) but also IRF5 and TLR4, key inducers for M1 dominant molecules (IL-1β, TNFα, CCL3, and CCL4), are upregulated in the SCN after HFD feeding, indicating that accumulated macrophages polarize to the M1 state. In addition, M1 dominant markers were also upregulated in parallel with the increase of macrophage markers in the SCN, and the ablation of macrophages by perineural administration of Mac1-Sap significantly suppressed the upregulation of M1 dominant molecules and improved established mechanical allodynia after HFD feeding. It is important that plasma concentration of TNFα and the mRNA expression level of TLR4 in monocytes are significantly higher in patients with diabetic peripheral neuropathy compared with healthy volunteers (Zhu et al., 2017), supporting our results. These lines of evidence suggest that macrophage-driven neuroinflammation in the SCN mediates T2DM-related neuropathic pain. Interestingly, these neuroinflammatory events were observed in the SCN, but not in other peripheral nerves such as trigeminal nerves. Although the region-specific mechanisms eliciting HFD-induced neuroinflammation are still unclear, this fact could correlate to the incidence of peripheral neuropathy in the feet of patients with T2DM (Gonçalves et al., 2017).

Growing evidence indicates that nAChR can be a negative regulator of inflammatory macrophages underlying intractable inflammatory diseases. We have previously demonstrated that the α4β2 subtype of nAChR mainly exerts anti-inflammatory effects on accumulated macrophages in the SCN after nerve injury (Saika et al., 2015; Kiguchi et al., 2018), whereas the α7 subtype has been a focus in other inflammatory diseases (Wang et al., 2003; Kox et al., 2011; Patel et al., 2017). Indeed, perineural administration of...
nicotine or TC-2559 significantly prevented neuropathic pain caused by SCN injury in mice (Saika et al., 2015; Kiguchi et al., 2018). We also revealed that activation of $\alpha_4\beta_2$ nAChR decreased under high expression of M1 dominant markers in LPS-stimulated macrophages in vitro, and such effects were mediated, at least in part, by inhibition of the janus kinase 2-signal transducer and activator of transcription 3 pathway, a key transcription factor for inflammatory processes (Kiguchi et al., 2015b). Hence, we sought to investigate the effects of TC-2559 on HFD-induced mechanical allodynia as a pharmacological inhibitor of inflammatory macrophages. Either perineural or systemic administration of TC-2559 effectively improved HFD-induced mechanical allodynia, and this improvement persisted long term, even after the cessation of administration, indicating that macrophages might contribute to the maintenance of T2DM-related neuropathic pain. So far, a direct relationship between inflammatory macrophages and mechanical allodynia has not fully determined. Inoculation of LPS-activated peritoneal macrophages into tissue surrounding the SCN showing M1 phenotype elicited mechanical allodynia, which is consistent with the results of macrophage ablation or inhibition. These results further support the premise that inflammatory macrophages directly contribute to mechanical allodynia, and that inflammatory macrophages are important for the pathogenesis of neuropathic pain caused not only by nerve injury but also by T2DM. Unlike type 1 diabetes mellitus, the pathophysiology of T2DM is closely related to obesity in patients, and it is well known that adipose tissues exacerbate insulin resistance and hyperglycemia (Kahn and Flier, 2000; Martyn et al., 2008). Therefore, the HFD feeding model, which shows not only hyperglycemia but also obesity, is commonly used as an experimental mouse model of T2DM. In our results, the induction of mechanical allodynia did not completely correlate to the time course of macrophage accumulation. Nevertheless, the induction period is consistent with other reports using similar HFD feeding models (Jayaraj et al., 2018). These lines of evidence suggest that the molecular mechanisms of mechanical allodynia in the induction phase might be different from those in the maintenance phase. Based on our functional study, inflammatory macrophages might play a significant role in the maintenance phase of HFD-induced allodynia. Obesity is defined by the activation and hypertrophy of adipocytes consisting of a large amount of fat, and it is facilitated by chronic inflammation (Weisberg et al., 2003). In particular, cross talk between adipocytes and macrophages through the cytokine-chemokine network has been extensively investigated (Wellen and Hotamisligil, 2003; Xu et al., 2003; Nishimura et al., 2008;
In addition, adipocytes produce typical adipokines (i.e., leptin and adiponectin) that have several physiologic and pathologic functions (Falcão-Pires et al., 2012). Accumulating evidence suggests that adipokines act as a key regulator of inflammation and significantly participate in the pathophysiology of inflammatory diseases (Fantuzzi, 2005; Ouchi et al., 2011). Importantly, adipokines including leptin contribute to pathologic pain by the direct activation of macrophages and pain-processing neurons (Maeda et al., 2009). In this T2DM model, obesity-driven actions might be important for regulating both hyperglycemia and neuropathic pain. However, this is not clear and should be determined in future studies. Recent reports demonstrate that sensory processing is altered by HFD feeding and that excessive innervation of sensory neurons to the skin may underlie abnormal hypersensitivity (Jayaraj et al., 2018). In terms of macrophage-driven neuroinflammatory events in the peripheral nerves, it is worth understanding the relationship between these phenomena and inflammatory macrophages.

In conclusion, inflammatory macrophages accumulated in the SCNs mediate the pathophysiology of neuropathic pain associated with T2DM. Neuroinflammation driven by inflammatory macrophages through a cytokine-chemokine network plays a crucial role in neuropathic pain not only in nerve injury, but also in T2DM; this is supported by the fact that the ablation or inhibition of accumulated inflammatory macrophages significantly improved neuropathic pain. Moreover, the ability of macrophages to induce neuropathic pain is also confirmed by evidence showing that the inoculation of activated inflammatory macrophages elicits mechanical allodynia under normal conditions. Collectively, the functional significance of inflammatory macrophages for the peripheral regulation of neuropathic pain is clearly determined and such events are commonly observed not only in nerve injury–related neuropathic pain, but also in T2DM-related neuropathic pain. We propose that pharmacological inhibition of macrophages themselves or macrophage-derived cytokines and chemokines could be a potential novel candidate in pharmacotherapy against several kinds of neuropathic pain.

Acknowledgments

We thank Prof. Takehiko Maeda (Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan) and Prof. Toshio Shimokawa for their helpful discussions and comments.
Macrophages Mediate Neuropathic Pain in Type 2 Diabetes

(Wakayama Medical University) for data analysis and suggestions. We also thank Editage for editing this manuscript.

Authorship Contributions

Participated in research design: Kiguchi and Kishioka.

Conducted experiments: Saika, Kiguchi, Matsuzaki, and Kobayashi.

Performed data analysis: Saika, Kiguchi, and Matsuzaki.

Wrote or contributed to the writing of the manuscript: Saika, Kiguchi, and Kishioka.

References


Address correspondence to: Dr. Norikazu Kiguchi, Wakayama Medical University, 811-1 Kimiidera, Wakayama City, Wakayama 641-0012, Japan.
E-mail: kiguchi@wakayama-med.ac.jp